Iovance Biotherapeutics ( (IOVA)) has released its Q3 earnings. Here is a breakdown of the information Iovance Biotherapeutics presented to its investors. Iovance Biotherapeutics, Inc. is a commercial ...

Revenue was above the high end of our quarterly guidance, with mid-teens organic revenue growth. We were once again GAAP ...

Operator: Good day, and welcome to the International General Insurance Holdings Ltd.’s Third Quarter 2024 Financial Results ...

British Airways owner International Airlines Group reported strong demand over the summer quarter with operating profits up ...

Columbia Bond Fund returned 6.02% during the quarter ended September 30, 2024, outperforming the fund’s benchmark, the ...

Aurinia Pharmaceuticals reported significant financial growth in Q3 2024, with net product revenue up by 36% ... expecting ...

Energy Transfer's Q3 report shows a 12% YoY growth in adjusted EBITDA, driven by strong crude oil transportation and NGL ...

Dynavax Technologies (NASDAQ: DVAX) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET ...

Duncan joined Techopedia as Senior EU Editor in July 2024. He has previously worked for the Telegraph Media Group and a ...

Secondly, we achieved another quarter of industry-leading loss ratios, driven by continued strong performance on both PMPM ...

Palantir’s Q3 shows strong AI-driven growth and profitability, but its high valuation raises concerns. Explore insights on ...

DraftKings reported a net income loss of $293.7 million in Q3 as the revenue costs reached $742.4 million, up 36.7% year-over ...